AU2020271839B2 - Prophylactic efficacy of serotonin 4 receptor agonists against stress - Google Patents

Prophylactic efficacy of serotonin 4 receptor agonists against stress Download PDF

Info

Publication number
AU2020271839B2
AU2020271839B2 AU2020271839A AU2020271839A AU2020271839B2 AU 2020271839 B2 AU2020271839 B2 AU 2020271839B2 AU 2020271839 A AU2020271839 A AU 2020271839A AU 2020271839 A AU2020271839 A AU 2020271839A AU 2020271839 B2 AU2020271839 B2 AU 2020271839B2
Authority
AU
Australia
Prior art keywords
stress
mice
administered
induced
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020271839A
Other languages
English (en)
Other versions
AU2020271839A1 (en
Inventor
Briana K. CHEN
Denis J. DAVID
Christine A. DENNY
Charlène FAYE
Alain M. GARDIER
Indira MENDEZ-DAVID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Columbia University
Research Foundation For Mental Hygiene
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Columbia University
Research Foundation For Mental Hygiene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Columbia University, Research Foundation For Mental Hygiene filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of AU2020271839A1 publication Critical patent/AU2020271839A1/en
Application granted granted Critical
Publication of AU2020271839B2 publication Critical patent/AU2020271839B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020271839A 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress Active AU2020271839B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962831517P 2019-04-09 2019-04-09
US62/831,517 2019-04-09
US201962857075P 2019-06-04 2019-06-04
US62/857,075 2019-06-04
US201962910859P 2019-10-04 2019-10-04
US62/910,859 2019-10-04
PCT/US2020/027321 WO2020210393A1 (en) 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress

Publications (2)

Publication Number Publication Date
AU2020271839A1 AU2020271839A1 (en) 2021-11-04
AU2020271839B2 true AU2020271839B2 (en) 2025-04-24

Family

ID=72750568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020271839A Active AU2020271839B2 (en) 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress

Country Status (8)

Country Link
US (1) US20220031684A1 (enExample)
EP (1) EP3952852B1 (enExample)
JP (1) JP7683882B2 (enExample)
CN (1) CN113924087A (enExample)
AU (1) AU2020271839B2 (enExample)
CA (1) CA3136328A1 (enExample)
MX (1) MX2021012394A (enExample)
WO (1) WO2020210393A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7821116B2 (ja) * 2020-04-07 2026-02-26 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
EP4577305A4 (en) * 2022-08-25 2026-07-29 Univ Columbia COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ANOTHER NEURODEGENERATIVE DISEASE
CN118105081B (zh) * 2024-03-04 2025-02-11 天津大学 一种情绪状态与神经电生理状态调节装置、验证系统及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US20180325844A1 (en) * 2015-11-17 2018-11-15 The Trusttees of Columbia University in the City of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US20180325844A1 (en) * 2015-11-17 2018-11-15 The Trusttees of Columbia University in the City of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FAYE, C. et al. European Neuropsychopharmacology (2018) Vol.28 Supplement 1, pages 521 to 522, Poster P.2.001, https://doi.org/10.1016/j.euroneuro.2017.12.040 *

Also Published As

Publication number Publication date
MX2021012394A (es) 2022-01-19
JP2022527865A (ja) 2022-06-06
EP3952852B1 (en) 2026-07-22
WO2020210393A1 (en) 2020-10-15
CA3136328A1 (en) 2020-10-15
EP3952852A4 (en) 2023-01-04
AU2020271839A1 (en) 2021-11-04
CN113924087A (zh) 2022-01-11
US20220031684A1 (en) 2022-02-03
JP7683882B2 (ja) 2025-05-27
EP3952852A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
Sales et al. Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels
US11110070B2 (en) Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
Wolff et al. Ketamine: from medicine to misuse
Mitchell et al. Good night and good luck: norepinephrine in sleep pharmacology
US12239614B2 (en) Pharmacological prophylactics against stress-induced affective disorders in females
JP7821116B2 (ja) ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
US20220031684A1 (en) Prophylactic efficacy of serotonin 4 receptor agonists against stress
KR20100059830A (ko) 도파민 수용체 리간드를 함유하는 약학적 조성물 및 도파민 수용체 리간드를 사용한 치료 방법
CA2708323C (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
US20220071932A1 (en) Compositions and Methods Against Stress-Induced Affective Disorders and Their Associated Symptoms
Beretta et al. Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K)
US9517265B2 (en) Methods for the prevention and/or treatment of memory impairment
US20220000805A1 (en) Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
JP2022527386A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
US20200316087A1 (en) Novel combination therapy for anxiety disorders, epilepsy, and pain
Brandt Critical review report: 3-Methylmethcathinone (3-MMC)
WO2023215342A1 (en) Compositions and methods for treating trigeminal neuralgia
Cruz Impact of Psychoactive Drugs on Mental Health
Shaw et al. Psychopharmacology in the physically ill child
Freeman et al. Myths and Realities of Pharmacotherapy in the Military
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Linge Méndez et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
De Leo et al. Psychopharmacological treatments of the elderly

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)